Odyssey Group International, Inc. (OTC: ODYY↑), was formed as a publicly held holding company with an emphasis on the development and acquisition of medical devices and health related technologies. The Company is focused on building and acquiring assets in areas that have an identified technological advantage and a substantial market opportunity within significant target markets across the globe.
The Company’s initial product technology is the CardioMap® heart monitoring and screening device, and is set to capitalize on the multi-billion dollar cardiology market. The Company has recently partnered with Prevacus Inc., who has been developing a nasal spray to treat concussions. Additionally, Odyssey Group has acquired Second Chance, who has developed a personal anti-choking device to save lives.